Advancing toward
more elegant solutions
Meaningful advancement requires radically different thinking
~50% of clinical research in NMIBC remains focused on early generation immunotherapy, a therapeutic category that also includes intravesical BCG1
Oncolytic immunotherapy is a highly advanced
area of research in NMIBC
3 decades of extensive research and clinical trials have established oncolytic immunotherapy as a promising treatment modality for cancer2
An intriguing approach in bladder cancer
Oncolytic immunotherapy can be engineered to leverage the retinoblastoma (Rb)-E2F pathway alterations that are highly correlated with NMIBC3,4
A selective, anti-tumor effect utilizing this pathway could be achieved with an oncolytic immunotherapy that includes certain properties3
Selectivity
Targets and kills cancer cells while sparing normal ones, minimizing off-target effects and toxicities3
Replication
Conditionally replicates within cancer cells to enhance the clinical potential5
Amplification
Efficiently spreads to and kills bystander cancer cells, amplifying the anti-tumor effect in the tumor microenvironment3
Stimulation
Stimulates a potent anti-tumor immune response to further eradicate cancer cells5
CG Oncology believes that every bladder is precious
It’s why we are 100% focused on exploring highly promising and novel approaches that have the potential to radically improve the lives of patients with bladder cancer
Learn about how demographics can
influence care
To learn more about the CG Oncology clinical program, contact Medical Affairs at medicalaffairs@cgoncology.com
BCG=bacillus Calmette-Guérin; NMIBC=non-muscle invasive bladder cancer.
The information on this site is intended for audiences in the United States only. The content on this site may not apply to non-U.S. audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.
The content on this website is for your information. It is not intended to be a substitute for professional medical advice, diagnosis or treatment.
REFERENCES:
1. Hannouneh ZA, Hijazi A, Alsaleem AA, et al. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Cancer Med. 2023;(24):21944-21968.
2. Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers (Basel). 2021;13(21):5452.
3. Yan Z, Zhang Z, Chen Y, Xu J, Wang J, Wang Z. Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments. Cancer Cell Int. 2024;24(1):242.
5. Zhang Y, Li Y, Chen K, Qian L, Wang P. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int. 2021;21(1):262.